Building of Lonza's new Cell Therapy facility in Singapore begins

Published: 8-Sep-2009
Media

Lonza Group Ltd has begun building a new facility for its Cell Therapy business, located at Tuas Biomedical Park in Singapore, adjacent to Lonza&\'s large-scale mammalian manufacturing facility.


Lonza Group Ltd has begun building a new facility for its Cell Therapy business, located at Tuas Biomedical Park in Singapore, adjacent to Lonza's large-scale mammalian manufacturing facility.

At a groundbreaking ceremony, Stefan Borgas, ceo of Lonza, said the new Cell Therapy manufacturing facility "is a next step in fulfilling our strategy to expand our capacity globally and our presence in Asia." He added that, "cell therapy is expected to be one of the most important innovation drivers of modern medicine and this new facility reinforces Lonza's leading position as a custom manufacturer of cellular therapeutics".

The facility is expected to begin manufacturing therapies within the first two suites by mid-2011. Designed to accommodate additional suites to meet incremental customer demand, the total investment for the first phase will be approximately CHF 30m (€20m).

Lonza, has 12 existing cGMP-certified cell therapy manufacturing suites in the US and Europe.

  • Companies:
  • Lonza
See more

You may also like

Media

Lonza receives approval for acquisition of Capsugel

Read more
Following the closing of the Capsugel acquisition, Lonza will further strengthen its position as a trusted supplier to the pharmaceutical, biotech and specialty ingredients markets

Trending Articles

  1. Can Aztekin receives Rising Star Award 2025 from the International Society of Regenerative Biology
  2. Royal Society of Chemistry and TIB co-create next generation Open Access consortium model The agreement delivers shared goals of equity for institutions, a community approach and universal open access for authors
  3. BioIVT acquires Optivia Biotechnology The acquisition strengthens BioIVT’s transporter sciences capabilities and will enable it to partner with customers on new drug applications and mechanistic studies related to transporters
  4. The Lab Awards: from balances to the ball The Lab Awards, the leading awards ceremony for the UK’s laboratory industry, was held at The Vox, Birmingham, on 1 November and celebrated the lab industry’s key achievements from the past year
  5. Reaping the benefits of a continuous process Growing interest in continuous processing reflects expectations that technological innovation can benefit operations across the board, says Guy Tiene, That’s Nice Director of Strategic Content

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Media

Lonza receives approval for acquisition of Capsugel

Following the closing of the Capsugel acquisition, Lonza will further strengthen its position as a trusted supplier to the pharmaceutical, biotech and specialty ingredients markets
Media

Lonza acquires cell and gene contract manufacturer PharmaCell

Lonza successfully completed the acquisition of PharmaCell B.V., one of the most successful cell and gene contract manufacturers in Europe
Media

Lonza acquires stake in Cilian

<p>In the wake of the withdrawal of its bid for Patheon, Swiss company Lonza has signed an investment agreement with German biotech company Cilian. The collaboration provides access to a prospective technology platform for innovative applications in the nutrition and biopharmaceutical area.</p>
Media

Lonza upgrades software at New Hampshire plant with Emerson

<p>Lonza, a global biopharmaceutical manufacturer with headquarters in Basel, Switzerland, is installing manufacturing operations management software from Emerson Process Management to enhance plant operations at its large-scale cell culture facility in Portsmouth, New Hampshire. </p>
Media

Lonza starts up second phase of Nansha API facility

<p>Swiss pharmaceutical firm Lonza is continuing its expansion in China with the start-up of the second phase of its large-scale API facility in Nansha. </p>
Media

Lonza launches XSpedite Microbial Services for pre-clinical quantities

<p>Swiss firm Lonza has introduced a fixed-price manufacturing service for rapidly delivering quantities of microbially derived biopharmaceuticals (up to 1,000mg). The company guarantees a minimum quantity will be delivered after an initial lab evaluation. </p>
Media

Lonza puts its custom manufacturing businesses into a single division

<p>Lonza, the Swiss pharmaceutical company, has combined its Exclusive Synthesis and Biopharmaceutical business divisions into a single entity called Lonza Custom Manufacturing in order to improve efficiency. </p>
Subscribe now